IGF1R and Ewing sarcoma: However, despite the numerous potential candidates for combination therapy with anti-IGF-1R antibodies, it is necessary to take into account the mixed results of preclinical and clinical studies as well as the modest biological evidence underlying IGF-1R as a target for Ewing sarcoma therapy.